Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases

NCT07143045 is registered in ClinicalTrials.gov with Alpha Biopharma (Jiangsu) Co., Ltd. as lead sponsor.

NCT NCT07143045
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07143045 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
Lead sponsor
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase
Observational
Overall status
Recruiting
Start date
December 29, 2025
Completion date
November 30, 2031
Enrollment
800 (estimated)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system (cns) metastases, egfr mutant advanced non-small cell lung cancer